614 related articles for article (PubMed ID: 33859638)
1. Cancer Vaccines, Adjuvants, and Delivery Systems.
Paston SJ; Brentville VA; Symonds P; Durrant LG
Front Immunol; 2021; 12():627932. PubMed ID: 33859638
[TBL] [Abstract][Full Text] [Related]
2. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
3. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
4. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
5. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
6. Synthetic and immunological studies on the OCT4 immunodominant motif antigen-based anti-cancer vaccine.
Chen T; Liu K; Xu J; Zhan T; Liu M; Li L; Yang Z; Yuan S; Zou W; Lin G; Carson DA; Wu CCN; Wang X
Cancer Biol Med; 2020 Feb; 17(1):132-141. PubMed ID: 32296581
[No Abstract] [Full Text] [Related]
7. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice.
Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF
Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological effects of mRNA vaccines in malignant diseases.
Heine A; Juranek S; Brossart P
Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
[TBL] [Abstract][Full Text] [Related]
9. Technologies for enhanced efficacy of DNA vaccines.
Saade F; Petrovsky N
Expert Rev Vaccines; 2012 Feb; 11(2):189-209. PubMed ID: 22309668
[TBL] [Abstract][Full Text] [Related]
10. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
12. Current challenges for cancer vaccine adjuvant development.
Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
[TBL] [Abstract][Full Text] [Related]
13. Controlled delivery of antigens and adjuvants in vaccine development.
Zhao Z; Leong KW
J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
Sun X; Zeng L; Huang Y
J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
[TBL] [Abstract][Full Text] [Related]
15. Comparison of DNA and mRNA vaccines against cancer.
Jahanafrooz Z; Baradaran B; Mosafer J; Hashemzaei M; Rezaei T; Mokhtarzadeh A; Hamblin MR
Drug Discov Today; 2020 Mar; 25(3):552-560. PubMed ID: 31843577
[TBL] [Abstract][Full Text] [Related]
16. Costimulatory molecules in vaccine design.
Hodge JW; Schlom J
Ernst Schering Res Found Workshop; 2000; (30):23-52. PubMed ID: 10943315
[No Abstract] [Full Text] [Related]
17. Drug delivery issues in vaccine development.
Powell MF
Pharm Res; 1996 Dec; 13(12):1777-85. PubMed ID: 8987071
[TBL] [Abstract][Full Text] [Related]
18. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.
Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
